Fasudil trial for early Alzheimer's disease
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy, Mental health clinical trials.
This trial tests a medication called fasudil to see if it can help people with early Alzheimer's disease. It is for people who have early symptoms (mild cognitive impairment or mild dementia) and have biomarker evidence of Alzheimer's in their brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early Alzheimer's disease, such as mild cognitive impairment or mild dementia.
- You have had a positive test for Alzheimer's proteins (like amyloid or tau) in your brain, spinal fluid, or blood.
- You are at least 50 years old.
- You have a study partner (like a family member or friend) who can regularly help with the study visits.
- You are fluent in Norwegian.
- You are not pregnant and are using effective birth control if needed.
- You do not have major health problems like severe kidney or liver disease, poorly controlled diabetes, heart rhythm issues, or a recent stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This study tests a new medication, CORT108297, that may help protect the brain from the harmful effects of stress in people at risk for Alzheimer's disease. It is looking for adults age 55 and older who either have mild memory problems or are healthy but have a family history, APOE4 gene, or memory concerns.
Hear when a new Cognitive Decline, Mild trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.